Does the Khorana Risk Score accurately predict the risk of venous thromboembolism in patients with NSCLC and SCLC?
Patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
Khorana Risk Score (KRS) assessment and clinical characteristics evaluation
Incidence of venous thromboembolism (VTE)hard clinical
The Khorana Risk Score is insufficient on its own for predicting VTE in lung cancer patients, highlighting the need for updated risk stratification tools that incorporate additional clinical parameters.
This study highlights the limitations of the KRS in predicting risk of development of VTE in patients with NSCLC and SCLC and identifies multiple clinical parameters associated with increased risk of VTE. Development of further risk stratification tools incorporating these clinical factors in addition to those in the KRS should be considered.
Building similarity graph...
Analyzing shared references across papers
Loading...
Dougherty et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69a75b59c6e9836116a2289d — DOI: https://doi.org/10.3389/fonc.2025.1651192
Sean C. Dougherty
Rishika Singh
Caleb McKinney
Frontiers in Oncology
SHILAP Revista de lepidopterología
University of Virginia
University of Virginia Health System
Building similarity graph...
Analyzing shared references across papers
Loading...